Moderna (0QF) Stock Forecast & Price Target

38 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QF Analyst Ratings

Hold

1 Buy

12 Hold

2 Sell

Based on 15 analysts giving stock ratings to

Moderna

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QF Stock 12 Month Forecast

Average Price Target

€42.33

▼(-11.92% Downside)

Based on 15 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is €42.33 with a high forecast of €66.63 and a low forecast of €33.75. The average price target represents a -11.92% change from the last price of €48.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","31":"€31","43":"€43","55":"€55","67":"€67"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66.62784359,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€66.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.33297554769231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€42.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.74657013,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,31,43,55,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.15,50.494449506923075,51.83889901384615,53.18334852076923,54.527798027692306,55.87224753461538,57.21669704153846,58.56114654846154,59.90559605538461,61.25004556230769,62.59449506923077,63.938944576153844,65.28339408307693,{"y":66.62784359,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.15,48.62561350366864,48.10122700733728,47.57684051100592,47.05245401467455,46.52806751834319,46.00368102201183,45.47929452568047,44.95490802934911,44.43052153301775,43.90613503668639,43.38174854035503,42.85736204402367,{"y":42.33297554769231,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.15,47.965120779230766,46.78024155846154,45.59536233769231,44.410483116923075,43.22560389615384,42.04072467538462,40.855845454615384,39.67096623384616,38.486087013076926,37.30120779230769,36.11632857153846,34.931449350769235,{"y":33.74657013,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.61,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.12,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.62,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.995,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.52,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.835,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.645,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.715,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.2,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.095,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":64.01,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":49.15,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€66.63

Average Price Target€42.33

Lowest Price Target€33.75

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

―

Hold

―

Reiterated

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Edward Tenthoff

Piper Sandler

€66.63

Buy

38.63%

Upside

Reiterated

08/06/26

Piper Sandler Sticks to Its Buy Rating for Moderna (MRNA)

Eliana Merle

Barclays

€41.53

Hold

-13.58%

Downside

Reiterated

08/05/26

Moderna (MRNA) Receives a Hold from Barclays

Jessica Fye

J.P. Morgan

€34.61

Sell

-27.98%

Downside

Reiterated

08/04/26

J.P. Morgan Remains a Sell on Moderna (MRNA)

Geoff Meacham

Citi

€35.48→€51.92

Hold

8.03%

Upside

Reiterated

08/03/26

Moderna price target raised to $60 from $41 at CitiModerna price target raised to $60 from $41 at Citi

Terence Flynn

Morgan Stanley

€33.75

Hold

-29.78%

Downside

Assigned

08/03/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Moderna (NASDAQ: MRNA) and Stevanato Group (NYSE: STVN)

Tyler Van Buren

TD Cowen

€34.61

Hold

-27.98%

Downside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: BrightSpring Health Services, Inc. (NASDAQ: BTSG), Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

€38.94

Hold

-18.98%

Downside

Reiterated

07/31/26

Berenberg Bank Keeps Their Hold Rating on Moderna (MRNA)

Joseph Stringer

Needham

―

Hold

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Merit Medical Systems (NASDAQ: MMSI) and Moderna (NASDAQ: MRNA)

Alec Stranahan

Bank of America Securities

€32.88→€34.61

Sell

-27.98%

Downside

Reiterated

07/31/26

Bank of America Securities Remains a Sell on Moderna (MRNA)

Luca Issi

RBC Capital

€38.94

Hold

-18.98%

Downside

Reiterated

07/31/26

RBC Capital Keeps Their Hold Rating on Moderna (MRNA)

Courtney Breen

Bernstein

€38.94

Hold

-18.98%

Downside

Reiterated

07/22/26

Moderna (MRNA) Receives a Hold from Bernstein

Salveen Richter

Goldman Sachs

€42.4→€57.97

Hold

20.63%

Upside

Assigned

07/21/26

Moderna price target raised to $67 from $49 at Goldman SachsModerna price target raised to $67 from $49 at Goldman Sachs

Andrew Tsai

Jefferies

€38.94

Hold

-18.98%

Downside

Reiterated

06/16/26

Moderna flu vaccine briefing docs 'read favorably,' says JefferiesModerna flu vaccine briefing docs 'read favorably,' says Jefferies

Michael Yee

UBS

€38.94

Hold

-18.98%

Downside

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Mediwound (NASDAQ: MDWD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

―

Hold

―

Reiterated

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Edward Tenthoff

Piper Sandler

€66.63

Buy

38.63%

Upside

Reiterated

08/06/26

Piper Sandler Sticks to Its Buy Rating for Moderna (MRNA)

Eliana Merle

Barclays

€41.53

Hold

-13.58%

Downside

Reiterated

08/05/26

Moderna (MRNA) Receives a Hold from Barclays

Jessica Fye

J.P. Morgan

€34.61

Sell

-27.98%

Downside

Reiterated

08/04/26

J.P. Morgan Remains a Sell on Moderna (MRNA)

Geoff Meacham

Citi

€35.48→€51.92

Hold

8.03%

Upside

Reiterated

08/03/26

Moderna price target raised to $60 from $41 at CitiModerna price target raised to $60 from $41 at Citi

Terence Flynn

Morgan Stanley

€33.75

Hold

-29.78%

Downside

Assigned

08/03/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Moderna (NASDAQ: MRNA) and Stevanato Group (NYSE: STVN)

Tyler Van Buren

TD Cowen

€34.61

Hold

-27.98%

Downside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: BrightSpring Health Services, Inc. (NASDAQ: BTSG), Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

€38.94

Hold

-18.98%

Downside

Reiterated

07/31/26

Berenberg Bank Keeps Their Hold Rating on Moderna (MRNA)

Joseph Stringer

Needham

―

Hold

―

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Merit Medical Systems (NASDAQ: MMSI) and Moderna (NASDAQ: MRNA)

Alec Stranahan

Bank of America Securities

€32.88→€34.61

Sell

-27.98%

Downside

Reiterated

07/31/26

Bank of America Securities Remains a Sell on Moderna (MRNA)

Luca Issi

RBC Capital

€38.94

Hold

-18.98%

Downside

Reiterated

07/31/26

RBC Capital Keeps Their Hold Rating on Moderna (MRNA)

Courtney Breen

Bernstein

€38.94

Hold

-18.98%

Downside

Reiterated

07/22/26

Moderna (MRNA) Receives a Hold from Bernstein

Salveen Richter

Goldman Sachs

€42.4→€57.97

Hold

20.63%

Upside

Assigned

07/21/26

Moderna price target raised to $67 from $49 at Goldman SachsModerna price target raised to $67 from $49 at Goldman Sachs

Andrew Tsai

Jefferies

€38.94

Hold

-18.98%

Downside

Reiterated

06/16/26

Moderna flu vaccine briefing docs 'read favorably,' says JefferiesModerna flu vaccine briefing docs 'read favorably,' says Jefferies

Michael Yee

UBS

€38.94

Hold

-18.98%

Downside

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Mediwound (NASDAQ: MDWD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

3 Months

Mani ForooharLeerink Partners

Success Rate

29/49 ratings generated profit

Average Return

-10.15%

Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.18% of your transactions generating a profit, with an average return of -10.15% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

32/49 ratings generated profit

Average Return

-17.64%

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 65.31% of your transactions generating a profit, with an average return of -17.64% per trade.

2 Years

Mani ForooharLeerink Partners

Success Rate

34/49 ratings generated profit

Average Return

+4.42%

Copying Mani Foroohar's trades and holding each position for 2 Years would result in 69.39% of your transactions generating a profit, with an average return of +4.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QF Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QF has received 3 Buy Ratings, 33 Hold Ratings, and 9 Sell Ratings. 0QF average Analyst price target in the past 3 months is 42.33.

Each month's total comprises the sum of three months' worth of ratings.

0QF Financial Forecast

0QF Earnings Forecast

Next quarter’s earnings estimate for 0QF is -€1.00 with a range of -€1.38 to -€0.57. The previous quarter’s EPS was -€1.70. 0QF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year 0QF has Performed in-line its overall industry.

0QF Sales Forecast

Next quarter’s sales forecast for 0QF is €755.34M with a range of €715.60M to €816.67M. The previous quarter’s sales results were €125.47M. 0QF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year 0QF has Performed in-line its overall industry.

0QF Stock Forecast FAQ

What is DE:0QF’s average 12-month price target, according to analysts?

Based on analyst ratings, Moderna’s 12-month average price target is 42.33.

What is DE:0QF’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:0QF, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Moderna a Buy, Sell or Hold?

Moderna has a consensus rating of Hold, which is based on 1 buy ratings, 12 hold ratings and 2 sell ratings.

What is Moderna’s share price target?

The average share price target for Moderna is 42.33. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €66.63 ,and the lowest forecast is €33.75. The average share price target represents -11.92% Decrease from the current price of €48.06.

What do analysts say about Moderna?

Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Moderna?

To buy shares of DE:0QF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Moderna (0QF) Stock Forecast & Price Target

0QF Analyst Ratings

0QF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Moderna

0QF Analyst Recommendation Trends

0QF Financial Forecast

0QF Earnings Forecast

0QF Sales Forecast

0QF Stock Forecast FAQ

Detailed List of Analyst Forecasts